GLP-1 Evidence

Sigurtà

Effetti sekondarji tal-GLP-1, imrankati skont il-frekwenza

Effetti sekondarji gastrointestinali huma kważi universali u ġeneralment jistgħu jiġu ġestiti. L-avvenimenti rari li dominaw il-kopertura huma verament rari.

Aġġornat 3 min read 27 ċitazzjonijiet Saħħa tal-evidenza 4/5

Veduta mill-għoli ta' sodda tal-isptar u kaxxa f'kamra ta' ward kondiviża
玄史生 · CC0 · Wikimedia Commons

L-aktar komuni

Kważi kollox frekwenti huwa gastrointestinal, u kważi kollox joriġina direttament minn ħin ta' ġestjoni tal-ġastru. Matul il-programmi tal-provi, il-patt huwa konsistenti [5][6][8]:

Bandi ta' frekwenza tipika mill-provi randomizzati
EffettKemm hu komuniPatt
NauseaVerament komuni (tletin sa nofs)Jirnexxi wara kull pass tad-doża, imbagħad jissolva
DiarreaKomuniSpiss kmieni, ġeneralment transitorja
KostipazzjoniKomuniTista' tibqa'; spiss l-akbar lment fit-tul
VomitKomuniRelatata b'doża b'mod qawwi
Uġigħ fl-abdomen, refluss, burpingKomuniĠeneralment ħafif
Reazzjonijiet fil-post tal-injezzjoniRariĦafif
Tmiem minħabba effetti sekondarjiFtit fil-mijaOgħla fil-dożi għoljin

Il-fossa bejn "tletin fil-mija ta' nies iħossu morda" u "ftit fil-mija jieqfu" hija l-aktar numru utli hawn. Ħafna nies li jsiru nauseated jgħaddu minnha, ġeneralment għax titjieb.

L-aktar rari li n-nies jinkwetaw dwarhom

Pancreatite, mard tal-ġallbladder, tumuri tal-C-cell tal-thyroid u gastroparesi dominaw id-diskussjoni online b'mod eċċessiv għall-frekwenza tagħhom fid-data.

  • Mard tal-ġallbladder. Verament żdied, iżda dan huwa sostanzjalment konsegwenza ta' telf ta' piż rapidu nnifsu minflok tossiċità diretta tad-drug — telf ta' piż rapidu b'kull mezz iżid ir-riskju ta' ġallstones.
  • Pancreatite. Osservata b'attenzjoni madwar il-klassi kollha. Meta-analiżi kbar ta' provi ta' riżultati kardjovaskulari u tal-kidney ma produċewx is-sinjal li rapporti ta' każijiet bikrin implikaw [1].
  • Tumuri tal-C-cell tal-thyroid. Il-warning ġej minn studji ta' rodent. Ma traduxxewx f'sinjal uman demonstrat, iżda huwa għaliex id-drug huma kontraindikati ma' storja personali jew familjari ta' karċinoma medullari tal-thyroid jew MEN2.
  • Gastroparesi. Il-ħin ta' ġestjoni tal-ġastru huwa l-mekkaniżmu maħsub, kif kopert fuq il-paġna tal-mekkaniżmu. Gastroparesi severa persistenti hija ħaġa differenti u ħafna rari.

Assenza ta' sinjali ta' sigurtà kbar fid-data pool ta' provi

Kif jidher l-aġenti orali l-ġodda

L-agonisti tal-molekuli żgħar orali issa għaddew minn provi randomizzati kbar kemm fl-obesità kif ukoll fit-tip 2 diabetes bikri [2][3][4]. Il-profil ta' tolleranza tagħhom jidher bħal dawk li jinjetta — dominati mill-istess effetti gastrointestinali, bil-istess strateġija ta' żieda tad-doża. Li tkun pill ma jbiddilx il-mekkaniżmu, u għalhekk ma jbiddilx l-effetti sekondarji. Aktar dwar l-għażliet orali.

Fejn id-data tal-provi u l-ħajja reali jvarjaw

Il-popolazzjonijiet tal-provi huma skrinjati, superviżjati u żdiedu skont il-protokoll. Riveduta fl-2025 ta' użu u effettività reali sabet li l-immaġni ġenerali ta' sigurtà tibqa' barra mill-provi, iżda b'aktar varjabilità — imħeġġa minn żieda aktar mgħaġġla, interrompiment tad-doża, nuqqas ta' provvista u prodotti kumpluti ta' kontenut inċert [9]. Ħafna mill-aqwa riżultati rapportati barra mill-provi jinvolvu s-sors mhux preskritt minflok id-drug innifsu.

Tablets imsaħħra bil-film abjad miżmuma f'stripp ta' blister
Cindy Shebley · CC BY 2.0 · Wikimedia Commons

Mistoqsijiet komuni

Jekk il-nausea qatt tgħaddi kompletament?
Għal ħafna nies tissolva fi ġimgħat ta' doża speċifika, u terġa' lura għal ftit waqt kull żieda. Il-kostipazzjoni hija l-effett li huwa l-aktar probabbli li jibqa'.
Hija telf ta' xagħar effetti sekondarji?
Il-ħruq ta' xagħar huwa konsegwenza magħrufa tajjeb ta' telf ta' piż rapidu ġeneralment — telogen effluvium — minflok tossiċità speċifika tad-drug. Ġeneralment huwa temporanju.
Għandi nieqaf qabel l-operazzjoni?
Staqsi lill-anestesista tiegħek. Hemm gwida perioperattiva speċifika għax il-stomaku jista' ma jkunx vojt wara l-fasting standard.
Jekk l-effetti sekondarji jfissru li qed jaħdem?
Le. Nausea u t-telf ta' piż huma kemm relatati b'doża, iżda individwi jvarjaw ħafna f'kull wieħed. Ħafna nies jitilfu ħafna piż mingħajr ħafna nausea.
Il-provi li hemm wara din il-paġna Bar imwaħħal li juri l-kompożizzjoni tal-12 pubblikazzjoni ċċitata f'din il-paġna skont it-tip ta' studju. 1911meta-analysis (1)randomised trial (9)review (1)other (1)
9 pubblikazzjonijiet, 2018–2025. Hemm esperimenti hawn iżda ftit sintetizzar, għalhekk ir-riżultati individwali għadhom għandhom ħafna piż u jistgħu jinbidlu. Sors: il-lista ta' ċitazzjonijiet ta' din il-paġna, hawn taħt.

Referenzi

Kull ċitazzjoni hawn taħt tgħaqqad mal-record oriġinali peer-reviewed fuq PubMed jew permezz ta' DOI. Xejn hawnhekk m'għandux ikun sostitut għal parir mediku.

  1. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  2. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  3. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  4. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Stefanou MI, Theodorou A, Malhotra K, et al. · European stroke journal · 2024 · Meta-analysis DOIPubMed 38400569Full text
  5. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  6. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  7. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Rosenstock J, Yabe D, Cox D, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41765029
  8. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Cummings JL, Atri A, Sano M, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41865758
  9. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study Buse JB, Bajaj HS, Dalskov SM, et al. · The lancet. Diabetes & endocrinology · 2026 · Randomised controlled trial DOIPubMed 42251859
  10. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Hannon TS, Chao LC, Barrientos-Pérez M, et al. · Lancet (London, England) · 2025 · Randomised controlled trial DOIPubMed 40975112
  11. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Rosenstock J, Hsia S, Nevarez Ruiz L, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544435
  12. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  13. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Blüher M, Rosenstock J, Hoefler J, et al. · Diabetologia · 2024 · Randomised controlled trial DOIPubMed 38095657Full text
  14. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Butler J, Shah SJ, Petrie MC, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 38599221Full text
  15. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  16. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Wharton S, Blevins T, Connery L, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37351564
  17. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Heise T, Mari A, DeVries JH, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468322
  18. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Inagaki N, Takeuchi M, Oura T, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35914543
  19. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 34186022
  20. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34170647
  21. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Thomas MK, Nikooienejad A, Bray R, et al. · The Journal of clinical endocrinology and metabolism · 2021 · Randomised controlled trial DOIPubMed 33236115Full text
  22. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Yamada Y, Katagiri H, Hamamoto Y, et al. · The lancet. Diabetes & endocrinology · 2020 · Randomised controlled trial DOIPubMed 32333875
  23. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOIPubMed 31189511
  24. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  25. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies Thomsen RW, Mailhac A, Løhde JB, et al. · Diabetes, obesity & metabolism · 2025 · Review DOIPubMed 40196933Full text
  26. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083
  27. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes Aroda VR, Rosenstock J, Terauchi Y, et al. · Diabetes care · 2019 · Journal article DOIPubMed 31186300

Din il-paġna ġiet tradotta awtomatikament mill-Ingliż. Il-citazzjonijiet u n-numri mhumiex mibdula. Aqra l-original Ingliż jekk xi ħaġa taqra b'mod stramb. Aqra l-original Ingliż